share_log

JP Morgan Maintains Overweight on Neumora Therapeutics, Raises Price Target to $22

Benzinga ·  Mar 18 11:10

JP Morgan analyst Tessa Romero maintains Neumora Therapeutics (NASDAQ:NMRA) with a Overweight and raises the price target from $20 to $22.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment